Open Access
Off-Target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent
Author(s) -
Yili Xu,
Ona Barauskas,
Cynthia Kim,
Darius Babusis,
Eisuke Murakami,
Dmytro Kornyeyev,
Gary Lee,
George Stepan,
Michel Perron,
Roy Bannister,
Brian E. Schultz,
Roman Sakowicz,
Danielle Porter,
Tomáš Cihlář,
Joy Y. Feng
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02237-20
Subject(s) - prodrug , in vitro , virology , diastereomer , chemistry , adenosine , adenosine triphosphate , covid-19 , polymerase , coronavirus , pharmacology , biology , biochemistry , enzyme , medicine , stereochemistry , disease , pathology , infectious disease (medical specialty)
Remdesivir (RDV, GS-5734), the first FDA-approved antiviral for the treatment of COVID-19, is a single diastereomer monophosphoramidate prodrug of an adenosine analogue. It is intracellularly metabolized into the active triphosphate form, which in turn acts as a potent and selective inhibitor of multiple viral RNA polymerases.